Subscribe on your favorite platform:
[00:11] Introduction — Andrew Belli welcomes Jeff Allen, the president and CEO of Friends of Cancer Research.
[00:35] The 25th anniversary of Friends of Cancer Research — In the past 25 years, the organization was focused on FDA-related policy. How to accelerate the delivery of new medicines to patients as fast as possible is their ultimate goal.
[02:02] The origins of the accelerator — Since the outbreak of the COVID-19 pandemic, the world dealt with a completely unfamiliar situation from a biological pathogen standpoint and a societal standpoint. Friends of Cancer, alongside their partners, including the FDA, worked on collecting valuable data. Evaluating evidence together was critical to sort through that information so that the best decisions could be made.
[05:46] Pilot projects in oncology — Partnership was the heart of the real-world evidence pilot projects. The partners’ expertise willing to come together, share data, and drop competitive barriers has been a critical component of success.
[10:22] The Biden administration might catalyze oncology research — According to Jeff, the new administration’s arrival is a unique opportunity to provide a vehicle to accelerate the progress that has already been made in the field of research.
[15:14] The 21st Century Cures Act — Bringing innovation and bio-sciences to a more regular conversation is one of the most significant aspects of the bill.
[18:11] The future of cancer research and cancer care — Allen predicts reduced mortality, advancements in precision oncology. He also hopes to see many positive changes on different fronts.